Spatial-temporal change in quantitative total bone imaging (QTBI) and circulating tumour cells (CTCs) in metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide (ENZA)
G. Liu(University of Wisconsin Carbone Cancer Center), Robert Jeraj(University of Wisconsin–Madison), Anupama Singh(University of Wisconsin–Madison), Joshua M. Lang(University of Wisconsin–Madison), William Duggan(Cleveland Clinic), Jamie M. Sperger(University of Wisconsin–Madison), Christos E. Kyriakopoulos(Dana-Farber Cancer Institute), Tina Mayer(Hochschule Hannover), Katharina Modelska(FibroGen (United States)), Elisabeth I. Heath(The Barbara Ann Karmanos Cancer Institute), Anthony R. Porcari(Pfizer (United States)), Scott B. Perlman(University of Wisconsin–Madison)
Cited by 0
Related Papers
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
|New England Journal of Medicine|2014|2.8k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|1.6k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial
|Journal of Clinical Oncology|2018|1.1k
Gene expression patterns in human embryonic stem cells and human pluripotent germ cell tumors
|Proceedings of the National Academy of Sciences|2003|650